Spatial sequencing
Disclosed herein, inter alia, are compositions and methods of use thereof for interrogating a sample comprising a cell.
1. A method of sequencing a plurality of target RNA molecules of a cell in situ, said method comprising:
i) hybridizing an oligonucleotide primer consisting of DNA to each of the plurality of target RNA molecules in a cell, wherein the oligonucleotide primer comprises a first region at a 3′ end that hybridizes to a first complementary region of the RNA molecule, and a second region at a 5′ end that hybridizes to a second complementary region of the RNA molecule, wherein the second complementary region is about 10 to about 150 nucleotides in the 5′ direction with respect to the first complementary region;
ii) extending the 3′ end of the oligonucleotide primer along the RNA molecule to generate a complementary sequence, wherein extending consists of incorporating deoxyribonucleotides into the 3′ end of the oligonucleotide primer, and ligating the complementary sequence to the 5′ end of the oligonucleotide primer thereby forming a circular oligonucleotide consisting of DNA;
iii) amplifying the circular oligonucleotide by extending an amplification primer hybridized to the circular oligonucleotide with a strand-displacing polymerase, wherein the amplification primer extension generates an extension product comprising multiple complements of the circular oligonucleotide; and
iv) sequencing the extension product of step (iii) in the cell, wherein sequencing comprises sequencing by synthesis.
2. The method of claim 1 , wherein the cell is a bacterial cell, a fungal cell, a plant cell, a mammalian cell, a stem cell, an immune cell, a cancer cell, a viral-host cell, or a cell that selectively binds to a desired target.
3. The method of claim 2 , wherein the cell is a bacterial cell, a fungal cell, or a viral-host cell comprising a viral nucleic acid sequence, wherein the bacterial cell is a Bacteroides, Clostridium, Faecalibacterium, Eubacterium, Ruminococcus, Peptococcus, Peptostreptococcus, Bifidobacterium, Enterococcus faecalis, Escherichia coli, Enterobacter sp., Klebsiella sp., Staphylococcus aureus, Lactobacillus, Proteus mirabilis, Pseudomonas aeruginosa, Salmonella enterica , or Peptostreptococcus sp. cell, wherein the fungal cell is a Candida, Saccharomyces, Aspergillus, Penicillium, Rhodotorula, Trametes, Pleospora, Sclerotinia, Bullera , or a Galactomyces cell, and optionally wherein the viral nucleic acid sequence is from a Hepadnaviridae, Adenoviridae, Herpesviridae, Poxviridae, Parvoviridae, Reoviridae, Coronaviridae, or a Retroviridae virus.
4. The method of claim 1 , wherein the plurality of target RNA molecules comprise variable regions and constant regions of a nucleic acid molecule.
5. The method of claim 4 , wherein the variable regions and constant regions comprise regions of a VDJ recombination of a B cell or T cell.
6. The method of claim 1 , wherein the cell is a neuronal cell, an endothelial cell, epithelial cell, germ cell, plasma cell, a muscle cell, peripheral blood mononuclear cell (PBMC), a myocardial cell, cancer cell, or a retina cell.
7. The method of claim 1 , wherein the cell is permeabilized and immobilized to a solid support surface.
8. The method of claim 7 , wherein the surface comprises a patterned surface suitable for immobilization of a plurality of cells in an ordered pattern.
9. The method of claim 1 , wherein the oligonucleotide primer is about 50 to about 500 nucleotides in length.
10. The method of claim 1 , wherein the oligonucleotide primer is a single-stranded polynucleotide comprising at least one amplification primer binding sequence, at least one sequencing primer binding sequence, or both one amplification primer binding sequence and one sequencing primer binding sequence.
11. The method of claim 1 , wherein the circular oligonucleotide is about 100 to about 1000 nucleotides in length, about 100 to about 300 nucleotides in length, about 300 to about 500 nucleotides in length, or about 500 to about 1000 nucleotides in length.
12. The method of claim 1 , wherein the first complementary region of the oligonucleotide primer or the second complementary region of the oligonucleotide primer comprises about 5 to about 15 nucleotides.
13. The method of claim 1 , wherein amplifying comprises rolling circle amplification (RCA) or rolling circle transcription (RCT).
14. The method of claim 1 , wherein the extension product comprises three or more copies of the circular oligonucleotide.
15. The method of claim 1 , wherein sequencing comprises extending one or more sequencing primers hybridized to the extension product.
16. The method of claim 1 , wherein sequencing comprises extending a sequencing primer by incorporating a labeled nucleotide, or labeled nucleotide analogue and detecting the label to generate a signal for each incorporated nucleotide or nucleotide analogue, wherein the sequencing primer is hybridized to the extension product.
17. The method of claim 16 , wherein detecting comprises two-dimensional (2D) or three-dimensional (3D) fluorescent microscopy.
18. The method of claim 16 , wherein detecting comprises confocal microscopy, light sheet microscopy, or multi-photon microscopy.
19. A method of sequencing an agent-mediated nucleic acid sequence of a cell, said method comprising administering a genetically modifying agent to the cell, and sequencing an agent-mediated nucleic acid sequence of the cell in situ according to claim 1 .
20. A method of identifying a nucleic acid sequence as an agent-mediated nucleic acid sequence, said method comprising administering a genetically modifying agent to a cell, detecting whether an agent-mediated nucleic acid sequence is present in the cell by sequencing a plurality of target nucleic acids according to claim 1 , and identifying the nucleic acid sequence as an agent-mediated nucleic acid sequence when the presence of the agent-mediated nucleic acid is detected in the cell.
21. A method of identifying a cell that responds to a genetically modifying agent, said method comprising administering a genetically modifying agent to the cell, detecting whether an agent-mediated nucleic acid sequence is present in the cell by sequencing a plurality of target nucleic acids according to claim 1 , and identifying a cell that responds to a genetically modifying agent when the presence of the agent-mediated nucleic acid is detected in the cell.
22. A method of identifying an agent as a genetically modifying agent, said method comprising administering an agent to a cell, detecting whether an agent-mediated nucleic acid sequence is present in the cell by sequencing a plurality of target nucleic acids according to claim 1 , and identifying the agent as a genetically modifying agent when the presence of the agent-mediated nucleic acid is detected in the cell.
23. The method of claim 1 , wherein the extending of step ii) is performed with a M-MLV reverse transcriptase, or a Thermus thermophilus (Tth) DNA polymerase or mutant thereof.
24. The method of claim 1 , wherein the first complementary region and the second complementary region are about 10 to about 50 nucleotides apart.
25. The method of claim 1 , wherein all steps are performed in one or more wells of a multiwell container.
26. The method of claim 1 , wherein two or more oligonucleotide primers hybridize to different complementary regions of the same RNA molecule.
27. The method of claim 1 , further comprising identifying a protein in the cell, wherein detecting the protein comprises contacting the cell with a specific binding reagent and detecting said specific binding reagent, thereby identifying the protein in the cell.
28. The method of claim 1 , wherein amplifying the circular oligonucleotide comprises extending the amplification primer hybridized to the circular oligonucleotide with a strand-displacing polymerase and one or more modified nucleotides comprising a bioconjugate reactive group, wherein the amplification primer extension generates an extension product comprising one or more modified nucleotides comprising a bioconjugate reactive group.